Tenaya Therapeutics(US:TNYA) Globenewswire·2026-01-09 13:30Core Insights - Tenaya Therapeutics aims to build on positive interim results from its TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) in 2025, with plans to report longer-term follow-up data in 2026 [1][3] - The company raised $60 million in Q4 2025 to support its operations through mid-2027 [1][7] Clinical Development Updates - Tenaya expects to share interim data for Cohort 2 of the MyPEAK-1 trial and updates from Cohort 1 in the first half of 2026, with one-year data for Cohort 1 and two-year data for Cohort 2 anticipated in the second half of 2026 [6][12] - The MyPEAK-1 trial has shown that TN-201 was well tolerated, with no dose-limiting toxicities and significant increases in MyBP-C protein levels observed [6][8] - The RIDGE-1 trial for TN-401 is also progressing, with initial positive data reported and plans for further patient enrollment following a review by the Data Safety Monitoring Board (DSMB) [12][14] Financial Position - As of Q3 2025, Tenaya had $56.3 million in cash and equivalents, and the additional $60 million raised is expected to fund operations through mid-2027 [7][1] Regulatory and Strategic Plans - The company plans to pursue regulatory alignment for its lead gene therapy programs, TN-201 and TN-401, throughout 2026 [1][12] - Tenaya's gene therapies have received various designations from the FDA, including Fast Track and Orphan Drug designations, indicating their potential significance in treating rare diseases [8][11]